Literature DB >> 8770510

Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.

R Ikeda1, S Nishimura, A Nishikawa, T Shinoda.   

Abstract

A hybridoma (clone CRND-8) that produced agglutinating monoclonal antibody (MAb) against Cryptococcus neoformans serotype D was established by using a soluble capsular polysaccharide-keyhole limpet hemocyanin conjugate for immunization. The isotype was immunoglobulin M(kappa). Specificity was determined by cell slide agglutination and enzyme-linked immunosorbent assay (ELISA). In both tests, the MAb reacted to serotypes D and A-D but not to serotypes A, B, and C. Furthermore, the specificity of the MAb determined by ELISA was the same as that of polyclonal antibody factor serum (PAb factor) 8, which showed high-level reactivity with serotypes D and A-D. These results supported the deduced specificity of the PAb-based antigenic factor 8. A total of 15 isolates of serotypes D and A-D but no serotype A isolates reacted with the MAb in cell slide agglutination tests. CRND-8 MAb can be used in place of PAb factor 8 for serotyping C. neoformans isolates and for the analysis of the antigen 8 epitope.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770510      PMCID: PMC170253          DOI: 10.1128/cdli.3.1.89-92.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  21 in total

1.  Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.

Authors:  T F Eckert; T R Kozel
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

2.  Serologic grouping of Cryptococcus neoformans.

Authors:  D E Wilson; J E Bennett; J W Bailey
Journal:  Proc Soc Exp Biol Med       Date:  1968-03

Review 3.  Pathology of the mycoses in patients with the acquired immunodeficiency syndrome (AIDS).

Authors:  F W Chandler
Journal:  Curr Top Med Mycol       Date:  1985

4.  Epidemiologic differences between the two varieties of Cryptococcus neoformans.

Authors:  K J Kwon-Chung; J E Bennett
Journal:  Am J Epidemiol       Date:  1984-07       Impact factor: 4.897

5.  Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.

Authors:  F Dromer; J Salamero; A Contrepois; C Carbon; P Yeni
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

6.  Immune response to Cryptococcus neoformans soluble polysaccharide. I. Serological assay for antigen and antibody.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1972-01       Impact factor: 3.441

7.  Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates.

Authors:  R Ikeda; T Shinoda; Y Fukazawa; L Kaufman
Journal:  J Clin Microbiol       Date:  1982-07       Impact factor: 5.948

Review 8.  Primary cutaneous cryptococcosis and Cryptococcus neoformans serotype D.

Authors:  W Naka; M Masuda; A Konohana; T Shinoda; T Nishikawa
Journal:  Clin Exp Dermatol       Date:  1995-05       Impact factor: 3.470

Review 9.  Capsular polysaccharides of Cryptococcus neoformans.

Authors:  A K Bhattacharjee; J E Bennett; C P Glaudemans
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct

10.  Use of monoclonal antibodies in the assay of hepatitis B core antigen and antibody.

Authors:  Y Furuya; M Inoue; N Yoshihara
Journal:  Jpn J Med Sci Biol       Date:  1984-08
View more
  13 in total

1.  Monoclonal antibody 13F1 produces annular immunofluorescence patterns on Cryptococcus neoformans serotype AD isolates.

Authors:  W Cleare; M E Brandt; A Casadevall
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

2.  Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.

Authors:  Marcellene A Gates-Hollingsworth; Thomas R Kozel
Journal:  Mol Microbiol       Date:  2009-09-02       Impact factor: 3.501

3.  Cas3p belongs to a seven-member family of capsule structure designer proteins.

Authors:  Frédérique Moyrand; Yun C Chang; Uwe Himmelreich; Kyung J Kwon-Chung; Guilhem Janbon
Journal:  Eukaryot Cell       Date:  2004-12

4.  UGD1, encoding the Cryptococcus neoformans UDP-glucose dehydrogenase, is essential for growth at 37 degrees C and for capsule biosynthesis.

Authors:  Frédérique Moyrand; Guilhem Janbon
Journal:  Eukaryot Cell       Date:  2004-12

5.  Distinct and redundant roles of exonucleases in Cryptococcus neoformans: implications for virulence and mating.

Authors:  Carolin Wollschlaeger; Nuria Trevijano-Contador; Xuying Wang; Mélanie Legrand; Oscar Zaragoza; Joseph Heitman; Guilhem Janbon
Journal:  Fungal Genet Biol       Date:  2014-09-28       Impact factor: 3.495

6.  Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier.

Authors:  Caroline Charlier; Fabrice Chrétien; Marielle Baudrimont; Elodie Mordelet; Olivier Lortholary; Françoise Dromer
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

7.  Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.

Authors:  T Belay; R Cherniak; T R Kozel; A Casadevall
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

8.  The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays.

Authors:  W Cleare; A Casadevall
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

9.  Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates.

Authors:  S P Franzot; I F Salkin; A Casadevall
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Genetic relationship between Cryptococcus neoformans var. neoformans strains of serotypes A and D.

Authors:  S P Franzot; B C Fries; W Cleare; A Casadevall
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.